Olema Oncology reported a net loss of $73.6 million for Q3 2026, driven by increased enrollment in its Phase 3 OPERA-01 and OPERA-02 trials for palazestrant, a breast cancer drug candidate. The company ended the quarter with $413.8 million in cash and expects to announce top-line Phase 3 OPERA-01 data in Q1 2027. Olema is also advancing OP-3136, a novel cancer therapy, and recently appointed Jason O’Byrne as CFO to support its growth. These developments position Olema to potentially transform metastatic breast cancer treatment with palazestrant and expand its oncology pipeline.
Olema Oncology's Q3 2026 financial results provide context for readers interested in health sector developments. For readers following health stocks, here is Pluang's market snapshot as of Nov 10, 2026 17:51 WIB: Among 150 priced health-sector US stocks tradable on Pluang, 76 rose and 58 fell today. Notable movers include LFST at USD 14.81 with a 1-day change of +1.44%, MRNA at USD 272.82 with a 1-day change of +1.42% and a Pluang order activity split of 49% Sell / 51% Buy, and ENVB at USD 1.46 with a 1-day change of +1.39%.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
